[Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
摘要
Hereditary hemorrhagic telangiectasia(HHT) is an autosomal disorder characterized by hemorrhage and abnormal blood vessels. Spontaneous recurrent epistaxis is the most common manifestation, and the severity of nosebleed develops with age increasing. However, there is no effect treatment for HHT-related epistaxis until now. Recently, bevacizumab shows significant effect in the treatment of HHT and the related literatures are increasing gradually. This article will review the studies focused on bevacizumab in the treatment of HHT-related refractory nasal bleeding.
引用本文（GB/T 7714）
Cong Xu, Hong-tian Wang. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].[J]. PubMed, 2016.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。